Browse by Audience
Skip to content
Papers of the Week
Peripherally acting anti-CGRP monoclonal antibodies attenuate cortical resting-state connectivity in migraine patients.
Authors
Szabo E, Bolo NR, Borsook D, Burstein R, Ashina SAbstract
In about half of migraine patients, anti-calcitonin gene-related peptide monoclonal antibodies reduce monthly migraine days by >50%. In these patients, this class of drugs may change cortical functions by decreasing nociceptive afferent barrage. This prospective study investigated functional connectivity changes in treatment responders after three-month treatment with galcanezumab.